Administration of BoxA in the heart reverses cardiac hypertrophy and delays heart failure (HF) induced by pressure overload, while recombinant HMGB1 aggravates it (Table 2) [109]. The gene discussed is HMGB1; the disease is cardiac hypertrophy.